Piperidinylalkylamide derivatives having multimodal activity against pain

A compound of Formula (I):

• wherein
• m is 0, 1, 2, 3, 4 or 5;
• n is 1, 2, 3, 4 or 5;
• X is a group selected from the group consisting of pyrimidine, pyrazine, oxadiazole, thiazole, thiadiazole, triazole and indazole;
• R1 is selected from the group consisting of substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
• wherein the alkyl, alkenyl or alkynyl in R1, if substituted, is substituted with one or more substituent/s selected from the group consisting of —OR4, —C(O)R4, halogen, —CN, C1-4 haloalkyl, C1-4 haloalkoxy and —NR4R4′;
• wherein R4 is selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl and unsubstituted C2-6 alkynyl;
• and R4′ is selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl and -Boc;
• R2 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;
• wherein the aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from the group consisting of halogen, —R5, —OR5, —NO2, —NR5R5′″, NR5C(O)R5′, —NR5S(O)2R5′, —S(O)2NR5R5′, —NR5C(O)NR5′R5″, —SR5, —S(O)R5, S(O)2R5, —CN, C1-4 haloalkyl, C1-4 haloalkoxy, —C(O)OR5, —C(O)NR5R5′, —OCH2CH2OH, —NR5S(O)2NR5′R5″ and —C(CH3)2OR5;
• and wherein the non-aromatic heterocyclyl in R2, if substituted, may also be spirosubstituted or substituted with ═O;
• wherein R5, R5′ and R5″ are independently selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl and unsubstituted C2-6 alkynyl;
• and wherein R5′″ is selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl and -Boc;
• R3 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;
• wherein the aryl or heterocyclyl in R3, if substituted, is substituted with one or more substituent/s selected from the group consisting of halogen, —R6, —OR6, —NO2, —NR6R6′″, NR6C(O)R6′, —NR6S(O)2R6′, —S(O)2NR6R6′, —NR6C(O)NR6′R6″, —SR6, —S(O)R6, S(O)2R6, —CN, C1-4 haloalkyl, C1-4 haloalkoxy, —C(O)OR6, —C(O)NR6R6′, —OCH2CH2OH, —NR6S(O)2NR6′R6″ and —C(CH3)2OR6;
• and wherein the non-aromatic heterocyclyl in R3, if substituted, may also be spirosubstituted or substituted with ═O;
• wherein R6, R6′ and R6″ are independently selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl and unsubstituted C2-6 alkynyl;
• and wherein R6′″ is selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl and -Boc;
• optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two of stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.